Order Now 1-800-246-8878

Early detection of colorectal cancer mutations from tissue samples

ColoScape™ Colorectal Cancer Mutation Detection Kit

ColoScape™ is a highly sensitive real-time PCR-based in vitro diagnostic assay for qualitative detection of colorectal cancer associated biomarkers in FFPE tissue samples. The kit utilizes DiaCarta’s proprietary QClamp® TaqMan-based PCR technology which leverages a sequence-specific clamp made by xeno-nucleic acid (XNA) to suppress PCR amplification of wild-type DNA template and selectively amplify only mutant DNA template. The detection kit identifies the presence or absence of mutations in the targeted regions. This technology enables a rapid, reproducible and affordable solution which employs a simple workflow and PCR machines that are commonly used in research labs.

Product specifications

Specification ColoScape™ Colorectal Cancer Mutation Detection Kit
Intended UseFor In Vitro Diagnostic Use (CE/IVD) or For Research Use
Sample TypeFFPE Tissues from Colorectal Cancer
Pack Size3 Samples; 21 Samples
Validated InstrumentsRoche LC 96, LC 480 II, and Bio-Rad CFX384
Detection ChannelFAM; HEX
Turnaround TimeLess than 3 hours
StabilityStable for 12 months at -25 ℃ to -15 ℃

Ordering information

Product Name Catalog # (RUO)Catalog # (CE/IVD)
ColoScape™ Colorectal Cancer Mutation Detection Kit (3 Samples) DC-30-0006R DC-30-0006E
ColoScape™ Colorectal Cancer Mutation Detection Kit (21 Samples) DC-30-0024R DC-30-0024E

Note: RUO (Research Use Only) products are not for use in diagnostic procedures. CE/IVD products are intended for use in diagnostic procedures.

Features and benefits


Aids colonoscopists in the diagnosis of serrated advanced adenomas


Proprietary XNA technology accurately identifies wild-type and mutant status of relevant genes


20 proprietary DNA markers from 4 genes


Less than 3 hours of assay run time


Highly sensitive detection utilizing XNA-based clamping technology


Increase probability of detection with at least one gene likely to be positive in >60% of advanced adenomas and >90% of colorectal cancer


Ready to run on most qPCR machines


ColoScape™ test is CE/IVD cleared

Supporting data

qPCR amplification curves generated by ColoScape™ on FFPE tissue.

ColoScape™ performance from FFPE samples. Pre-cancer detection sensitivity is 60% (6 out of 10 samples). Data from internal studies at DiaCarta.

Comparing the technical details and performance characteristics of ColoScape™ (DiaCarta) and Cologuard® (Exact Sciences). ColoScape™ data from an independent study performed by the University of Potsdam.